CNN TürkBitcoin ETF'lerinde 5 günlük bilanço! 510 milyon dolarlık çıkışUN NewsFormer UN rights chief awarded Nobel Peace PrizeDaily MaverickANTI-FOREIGNER UNREST: Home Affairs scraps asylum seeker directive after violence in Durban and SowetoThe Jerusalem PostParashat Bereishit: The world of waterRTP DesportoVillas-Boas diz que a venda de Rodrigo Mora evitaria prejuízo da FC Porto SADEl ComercioEcuador y los sofisticados drones Reaper: el objetivo es consolidar el control del mar, el aire y el territorioInquirerPiston protests World Bank-led transport conference in BaguioInquirer EntertainmentMiss Universe factions clash over 2027 host country claimsZDF heuteAktuelle Pressemitteilungen des ZDFColliderApple TV’s Biggest Series Officially Ends With One of Its Highest-Rated EpisodesGIGAZINEjevやGPT-6 Luna Decisionsなどの素早い判断に特化した確率モデルがパックマンをプレイするベンチマーク「jevman」VarietyGromit Speaks: Martin Freeman to Voice Beloved but Mute Dog in Audiobook Edition of Autobiography
The Daily Newsstand · Free, Always
Friday, October 9, 2026

Centre moves to bar retailers, wholesalers from advertising prescription drugs

Translate

The Centre has invited public feedback on the proposed rules within 30 days for final notification.

The draft rules on advertising restrictions have been issued following detailed consultations with the Drugs Technical Advisory Board. (Image: Pixabay)
The draft rules on advertising restrictions have been issued following detailed consultations with the Drugs Technical Advisory Board. (Image: Pixabay)

NEW DELHI: The health ministry has moved to plug a major regulatory loophole in the pharmaceutical supply chain by proposing stringent curbs on advertisements of prescription drugs by retailers, wholesalers and distributors, the government said on Friday.

The government wants to ensure that marketing curbs on potent medicines are no longer restricted to pharmaceutical manufacturers.

It said the draft rules proposing the change have been notified in the official gazette on 28 September. The draft rules have been issued following detailed consultations with the Drugs Technical Advisory Board (DTAB).

“Under the existing regulatory framework, pharmaceutical manufacturers are prohibited from advertising drugs covered under Schedule H, Schedule H1 and Schedule X without prior sanction of the Central Government. However, corresponding provisions have not explicitly covered entities engaged in the retail and wholesale sale and distribution of these medicines,” the health ministry said in a statement.

As part of the plan, the health ministry has proposed new regulatory measures under Rule 65 of the Drugs Rules, 1945.

“No advertisement of drugs specified in Schedule H, Schedule H1 or Schedule X shall be made except with the previous sanction of the Central Government,” the ministry said.

The Centre has invited objections and suggestions from stakeholders and members of the public on the proposed rules within 30 days. Submissions received within the prescribed period will be considered by the Central government before the amendment is finalized.

The measures cover all entities holding licences to sell, stock, exhibit, offer for sale or distribute medicines, effectively bringing brick-and-mortar chemists, large distributors and online pharmacy platforms under central scrutiny.

Mint reported on 21 November 2025 about the growing regulatory concerns over prescription drug promotions and the government’s intent to restrict advertising by distributors and retailers.

Stronger oversight

“The proposed amendment is intended to strengthen regulatory oversight across the pharmaceutical supply chain, discourage unauthorized promotion of prescription medicines and reduce risks associated with inappropriate self-medication,” the health ministry said.

The intervention is critical as Schedule H, Schedule H1, and Schedule X encompass potent substances that require strict medical oversight, ranging from critical antibiotics and anti-tuberculosis medicines to psychotropic and habit-forming drugs.

Highlighting these clinical risks, the ministry said the measure is expected to “reinforce safeguards relating to medicines that require appropriate medical supervision, including certain antibiotics, psychotropic medicines and other prescription-only drugs.”

The amendment stems from recommendations finalized during the 93rd meeting of the DTAB on 16 February, where drug experts flagged the absence of advertising provisions for distribution licence holders.

About the Author

Priyanka Sharma is a journalist at Mint, where she covers the Union Ministry of Health and the pharmaceutical industry. Her work focuses on explaining government policies and how they impact healthcare and the medicine market in India. With 12 years of experience in journalism, she has built a reputation for providing clear and honest news on important health topics that affect the entire country.<br><br>Her educational background includes a journalism degree from the prestigious Indian Institute of Mass Communication (IIMC) and specialized training in public health from the Public Health Foundation of India. Before her current role at Mint, Priyanka worked with India Today, The Pioneer, and ANI. She also served as a lead consultant for the National Health Authority, which gave her firsthand knowledge of how the government manages large-scale health programmes.<br><br>Priyanka is based in New Delhi and is an avid traveller who loves visiting the mountains. She has a great interest in regional flavours, particularly South Indian food.

View the original on Mint →

KioskNews shows a cleaned-up reading view extracted from the publisher’s page — the original always lives on their site, not ours.